A new Houston-based technology seeks to allow the body to produce its own diabetes-managing peptides.
Live Poll
Would you prefer a one-time treatment over recurring injections for chronic health management?
September 22, 2026
Most Diabetes Patients Struggled With New MedicationA new study found that many people starting combination therapy for type 2 diabetes face long-term adherence challenges.
September 22, 2026
FDA Issued Warning to Houston Pharmacy Over GLP-1 DrugsThe federal agency raised concerns about the manufacturing and clinical oversight of compounded medications for local patients.
September 21, 2026
Eli Lilly Began Construction on Houston Diabetes CampusThe 236-acre facility will produce orforglipron, an oral medication approved in 2026 for diabetes management.
